Loading...
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Coleman, R Oza, A Lorusso, D Aghajanian, C Oaknin, A Dean, A Colombo, N Weberpals, J Clamp, Andrew R Scambia, G
Coleman, R
Oza, A
Lorusso, D
Aghajanian, C
Oaknin, A
Dean, A
Colombo, N
Weberpals, J
Clamp, Andrew R
Scambia, G
Citations
Altmetric:
Abstract
Rucaparib, a poly(ADP-ribose) polymerase inhibitor, has anticancer activity in recurrent ovarian carcinoma harbouring a BRCA mutation or high percentage of genome-wide loss of heterozygosity. In this trial we assessed rucaparib versus placebo after response to second-line or later platinum-based chemotherapy in patients with high-grade, recurrent, platinum-sensitive ovarian carcinoma.
Authors
Coleman, R
Oza, A
Lorusso, D
Aghajanian, C
Oaknin, A
Dean, A
Colombo, N
Weberpals, J
Clamp, Andrew R
Scambia, G
Leary, A
Holloway, R
Gancedo, M
Fong, P
Goh, J
O'Malley, D
Armstrong, D
Garcia-Donas, J
Swisher, E
Floquet, A
Konecny, G
McNeish, I
Scott, C
Cameron, T
Maloney, L
Isaacson, J
Goble, S
Grace, C
Harding, T
Raponi, M
Sun, J
Lin, K
Giordano, H
Ledermann, J
Oza, A
Lorusso, D
Aghajanian, C
Oaknin, A
Dean, A
Colombo, N
Weberpals, J
Clamp, Andrew R
Scambia, G
Leary, A
Holloway, R
Gancedo, M
Fong, P
Goh, J
O'Malley, D
Armstrong, D
Garcia-Donas, J
Swisher, E
Floquet, A
Konecny, G
McNeish, I
Scott, C
Cameron, T
Maloney, L
Isaacson, J
Goble, S
Grace, C
Harding, T
Raponi, M
Sun, J
Lin, K
Giordano, H
Ledermann, J
Description
Date
2017-09-12
Publisher
Collections
Keywords
Type
Article
Citation
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. 2017, Lancet